English name: AzaSite
Specification: 2.5ml/bottle (1% concentration)
Indications: treatment of bacterial conjunctivitis
Usage and dosage: 1 eye drop, twice a day for 2 days; Then 1 drop, five times a day, one eye ***9 drops for a course of treatment.
Compared with oral dosage forms, the invention has the advantages of less dosage, less systemic side effects, direct eye absorption, rapid effective bacteriostatic concentration and rapid curative effect; Compared with eye gel or eye ointment, it has the advantages of convenient use and good patient tolerance. Its preparation process is reasonable and its performance is stable, thus ensuring the clarity and stability of eye drops.
At the end of April, 2007, FDA approved the marketing of 1% azithromycin eye drops of Inspire PHarmaceuticals (trade name: AzaSite) for the treatment of bacterial conjunctivitis. Compared with other antibiotic preparations used for bacterial conjunctivitis on the market at present, azastat can reduce the number of times of administration. In two phase III clinical studies, azalide reached the end point of judging the main curative effect of patients with bacterial conjunctivitis determined by clinical treatment. The most common adverse reaction of this product is eye irritation, and the incidence rate is 1% ~ 2%. In February 2007, Inspire Pharmaceutical Company obtained the exclusive agency of AzaSite in the United States and Canada from InSite Vision Company. AzaSite is adriamycin eye drops developed by Inset Vision Company using the new DuraSite ophthalmic drug delivery system. This product is protected by American patent until 20 19.